[Monoclonal antibodies of the IPO series in studying and diagnosing malignant lymphoproliferative diseases].
The authors have developed a panel of monoclonal antibodies (MCA) of IPO series (Institute of Problems of Oncology, Kiev). RPMI-1788 cell line, Daudi, as well as splenocytes of a patient with hairy-cell leukemia were used for immunization of mice. It has been shown that IPO-3, IPO-10 and IPO-24 MCA are directed against differentiation antigens of human B-lymphocytes. IPO-4 MCA reveal the antigen of activated T- and B-cells. IPO-5 and IPO-20 MCA recognize HLA-ABC, while IPO-37 a common leucocytic antigen. IPO-38 MCA are directed against the nuclear antigen. The possibilities of using IPO MCA in hematology have been discussed.
Sidorenko
S P
SP
Vetrova
E P
EP
Iurchenko
O V
OV
Shlapatskaia
L N
LN
Berdova
A G
AG
Elenskaia
A M
AM
Bal'shin
M D
MD
Gluzman
D F
DF
D000047:Academies and Institutes; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology; D003937:Diagnosis, Differential; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D008223:Lymphoma / Q000175:diagnosis* / Q000276:immunology; D008495:Medical Oncology; D051379:Mice; D014455:Ukraine
D000911:Antibodies, Monoclonal; D015703:Antigens, CD
Monoklonal'nye antitela serii IPO v izuchenii i diagnostike zlokachestvennykh limfoproliferativnykh zabolevaniĭ.